Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. today announced its exclusive ONE by ONE and Biotrue ® Eye Care Recycling programs have recycled a total of 41,358,603 million units, or 248,516 pounds, of used contact lens, eye and lens care materials. The programs are made possible through a collaboration with TerraCycle ® a world leader in the collection and repurposing of ...

- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health"), today announced its exclusive ONE by ONE and Biotrue ® Eye Care Recycling programs have recycled a total of 41,358,603 million units, or 248,516 pounds, of used contact lens, eye and lens care materials. The programs are made possible through a collaboration with TerraCycle ® a world leader in the collection and repurposing of hard-to-recycle post-consumer waste.

"An integral part of our commitment to helping people see better to live better is our focus on sustainability," said Joe Gordon , U.S. president, Bausch + Lomb. "With our ONE by ONE Recycling  program and the new Biotrue ® Eye Care Recycling program, we have greatly expanded the ways we can help reduce the environmental footprint of these materials in conjunction with eye care professionals, patients and consumers all across the United States . We're incredibly proud of the significant impact these programs have made to date, for the ongoing collaboration we have with TerraCycle, and we look forward to building upon them for years to come."

According to The Association of Plastic Recyclers, the industry standard screen size, which identifies and removes unrecyclable plastics, filters out small-sized materials as part of the recycling process 1 . Standard recycling facilities also only accept certain types of plastic. As a result, contact lens, eye and lens care materials don't typically end up getting processed and are diverted to landfills.

"Used contact lenses, eye and lens care products and the materials associated with them are waste streams that are often overlooked in standard recycling practices, which can have a tremendous impact on the buildup of environmental waste," said Tom Szaky, founder and CEO, TerraCycle. "Participating in these unique recycling programs we have with Bausch + Lomb offer people the ability to help ensure their eye health-related materials are properly recycled and don't end up in waterways and landfills."

Since launching earlier this year, the company's Biotrue ® Eye Care Recycling program, which is the first and only eye care recycling program in the United States , has collected more than 65,000 eye drop single dose units, lens cases and lens solution caps*, as well as Biotrue ® Hydration Boost Lubricant eye drops multi-dose bottles. The ONE by ONE Recycling program collected more than 41 million units of used contact lenses, top foils and blister packs since launching in 2016.

For more information on the ONE by ONE and Biotrue ® Eye Care Recycling programs, visit https://www.biotrue.com/recycling .

About the Biotrue ® Eye Care Recycling Program
The Bausch + Lomb Biotrue ® Eye Care Recycling program is the first and only eye care recycling program in the United States . This program allows consumers who participate to properly recycle all brands of their eye drop single dose units, lens cases and lens solution caps*, as well as Biotrue ® Hydration Boost Lubricant eye drops multi-dose bottles. Once consumers collect these items, they can be mailed to TerraCycle using a pre-paid shipping label. When the waste arrives at the TerraCycle facility, it is cleaned and melted into hard plastic pellets that can be used to make new recycled products.

About the ONE by ONE Recycling Program
The Bausch + Lomb ONE by ONE Recycling program is the first and only sponsored contact lens recycling program in the United States . This award-winning program collects used contact lenses, top foil and opened plastic blister packs from any brand and is available to contact lens wearers and eye care professionals. More than 7,000 eye care practices are registered as official recycling centers of the program. To participate, contact lens wearers can bring their used contact lenses and packaging to one of these practices, which collects the used lens materials in a custom recycling bin provided by Bausch + Lomb. Once the bin is filled, the optometry practice will ship the materials to TerraCycle for proper recycling using a pre-paid shipping label.

About TerraCycle
TerraCycle is an innovative waste management company with a mission to eliminate the idea of waste. Operating nationally across 20 countries, TerraCycle partners with leading consumer product companies, retailers and cities to recycle products and packages, from dirty diapers to cigarette butts, that would otherwise end up being landfilled or incinerated. In addition, TerraCycle works with leading consumer product companies to integrate hard to recycle waste streams, such as ocean plastic, into their products and packaging. Its new division, Loop, is the first shopping system that gives consumers a way to shop for their favorite brands in durable, reusable packaging. TerraCycle has won over 200 awards for sustainability and has donated over $44 million to schools and charities since its founding more than 15 years ago and was named #10 in Fortune magazine's list of 52 companies Changing the World. To learn more about TerraCycle or get involved in its recycling programs, please visit www.terracycle.com .

About Bausch + Lomb
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in approximately 100 countries. For more information, visit www.bausch.com .

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn .

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, launches and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

*Lens solution bottles can be recycled through standard recycling bins in accordance with each respective city/town's recycling guidelines.

References
1. The Association of Plastic Recyclers. "APR Design Guide"; Retrieved from: https://plasticsrecycling.org/hdpe-design-guidance . Assessed September 13, 2021 .

TerraCycle is a trademark of TerraCycle Inc.
Biotrue is a trademark of Bausch & Lomb Incorporated or its affiliates.
© 2021 Bausch & Lomb Incorporated or its affiliates.
BOD.2257.USA.21

Media Contact:

Bausch Health Investor Contact:

Sue Kauffman

Arthur Shannon

sue.kauffman@terracycle.com

arthur.shannon@bauschhealth.com

(609) 393-4252 x3708

(514) 865-3855


(877) 281-6642 (toll free)




Bausch Health Media Contact:


Lainie Keller


lainie.keller@bauschhealth.com


(908) 927-1198

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/bausch--lomb-reports-more-than-41-million-units-of-contact-lens-eye-and-lens-care-materials-recycled-through-one-by-one-and-biotrue-eye-care-recycling-programs-301423702.html

SOURCE Bausch Health Companies Inc.

News Provided by PR Newswire via QuoteMedia

IDBS Polar Insight Brings Advanced Data Analytics and Visualization to BioPharma Lifecycle Management

IDBS, a Danaher (NYSE:DHR) operating company, announced Polar Insight, bringing new advanced data analytics and visualization tools to the Polar BioPharma Lifecycle Management (BPLM) platform.

Extracting valuable insights from process and quality data across the biopharmaceutical lifecycle is a time consuming and error prone process, requiring laborious manual work and multiple steps.

Keep reading... Show less

Medtronic receives Health Canada licence for GI Genius intelligent endoscopy module with artificial intelligence system for colonoscopy

Transformative AI System Enhances Colorectal Cancer Detection Capabilities

 Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) — the global leader in medical technology — announced it has received a Health Canada licence for the GI Genius™ intelligent endoscopy module. GI Genius is a computer-aided detection (CADe) system that uses artificial intelligence (AI) to highlight regions of the colon suspected to have visual characteristics consistent with different types of mucosal abnormalities.

Keep reading... Show less
Beyond Medical Technologies Ramps Up COVID Mask Manufacturing in Response to New South Africa COVID Variant

Beyond Medical Technologies Ramps Up COVID Mask Manufacturing in Response to New South Africa COVID Variant

Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) ("Beyond Medical" or the "Company") is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. ("Micron Technologies").

Keep reading... Show less
Leveljump Q3 Earnings and Results; Record Quarterly Revenues

Leveljump Q3 Earnings and Results; Record Quarterly Revenues

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce today it has reported financial results for the third fiscal quarter ended September 30th, 2021. All amounts are expressed in Canadian dollars.

Financial and Operational Highlights

Keep reading... Show less

Thermo Fisher Scientific Confirms Detection of SARS-CoV-2 in Samples Containing the Omicron Variant with its TaqPath COVID-19 Tests

- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit *, and TaqPath COVID-19 CE-IVD RT-PCR Kit *, which test for the presence of SARS-CoV-2, are not impacted by the emerging B.1.1.529, or Omicron variant, enabling accurate test results.

The Omicron variant, which was designated a " variant of concern " by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone. The WHO has reported that preliminary evidence suggests an increased risk of transmission compared to other variants of concern. This designation and information are leading to renewed travel restrictions and research to examine the variant's impact on efficacy of existing vaccines and tests. The WHO and European Centers for Disease Control have both reported that using S-gene target failure (SGTF) of the PCR assays as a proxy for the variant helped to identify Omicron. Cases of the variant were first identified in South Africa and have now been reported in at least a dozen countries around the world.

Keep reading... Show less
UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical

UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that, subject to regulatory approval, it has agreed to acquire an outstanding 14.6% minority equity interest in Real Time Medical Inc. ("RTM"), a private Ontario company, in exchange for 2,494,576 units (a "Unit") of Leveljump. Each Unit will be issued at a price of $0.66 per Unit with each Unit being comprised of three (3) Leveljump common shares at a deemed price of $0.22 per share and one (1) share purchase warrant of Leveljump, each warrant entitling the holder to acquire one additional common share of Leveljump at a price of $0.35 per common share on or before December 31, 2023.

The equity interest in RTM was acquired through a mini-tender offer to the shareholders of RTM dated November 1, 2021 whereby JUMP offered to acquire up to 19.9% of RTM in exchange for the Units. The holders of the RTM shares who have tendered are all accredited investors.

Keep reading... Show less

Top News

Related News